HOHCells

HOHCells is an emerging private biotech tools company founded in 2018, commercializing a patented cryopreservation platform originating from academic research at the University of Maryland. Its core technology, FreezOpt™, addresses the significant cell loss (often ~50%) associated with conventional freezing methods by initiating consistent ice formation, which has been shown in peer-reviewed studies to nearly double viable cell recovery. The company targets the research tools market, serving academic labs, biotechs, and CDMOs to improve the efficiency and consistency of upstream process development for cell therapies and regenerative medicine. HOHCells appears to be in an early commercial stage, generating revenue through direct product sales while seeking partnerships for validation and distribution.

FreezOpt™, a proprietary non-chemical ice nucleation "seed" system designed to provide consistent, controlled initiation of ice formation during cryopreservation. This technology minimizes intracellular ice formation and cellular stress, dramatically improving post-thaw viability and recovery for stress-sensitive cells like stem cells and immune cells.

HOHCells competes in the life science research tools market against large reagent companies (e.g., Thermo Fisher, Corning) that offer standard cryopreservation media and protocols. Its differentiation is a physics-based, non-chemical nucleation technology with published superior recovery data, targeting a specific high-value niche within the broader cryopreservation market.